spacer
home > pmps > summer 2009 > lung power
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Lung Power

The technologies underpinning inhaled drug delivery have developed rapidly over the past decade as the pharmaceutical industry has moved to exploit the lungs as a route to rapidly introducing therapeutics into the body. Many locally acting and systemic drugs are now routinely delivered in this way. However, developing delivery devices and formulations that perform well is challenging, and is an area of continuing investment for the industry.

It seems timely, therefore, to review the evolution of delivery devices and the benefits provided by different designs as a prelude to considering key performance targets for inhalation systems and the in vitro analytical techniques used to ensure they are met.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Copley graduated from the University of Bath, UK in 2000 with a Masters Degree in Aerospace Engineering. For the past nine years he has been sales manager and product specialist for Copley Scientificís range of inhaler testing equipment and is now Sales Director for the company. Mark is considered a leading authority in testing methods and systems for metered-dose inhalers, dry powder inhalers, nebulisers and nasal sprays. He also provides application support and consultancy, and runs focused training courses and workshops for the inhaled drug testing sector of the pharmaceutical industry. An invited member of the European Pharmaceutical Aerosol Group (EPAG) impactor sub-team, Mark has also made contributions to the Inhalanda working group, leading to subsequent revisions to Ph Eur and USP monographs.
spacer
Mark Copley
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the companyís lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers
 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement